By addressing core deficits in bioenergetics, axonal degeneration, and synaptic connectivity, M1R/TRPM3 modulation represents a significant paradigm shift in the treatment of peripheral neuropathy—one that redefines therapeutic success in terms of regeneration and long-term functional recovery. This evidence concerns the gene TRPM3 and peripheral neuropathy.